• Home
  • Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.

Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.

Author List
Guglin M, Munster P, Fink A, Krischer J
Publication
American heart journal
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1211419
Publication Year
2017
PubMed ID
28577685
Publication Title
Guglin M, Munster P, Fink A, Krischer J. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am Heart J. 2017 Jun; 188:87-92.